Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
BLTE
BLTE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BLTE News
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript
Mar 03 2026
NASDAQ.COM
Belite Bio Reports Q4 2025 Earnings Highlights
Mar 03 2026
seekingalpha
Belite Bio Reports Q4 Non-GAAP EPS Beat Expectations
Mar 02 2026
seekingalpha
Belite Bio Completes Enrollment in DRAGON II Trial for Stargardt Disease
Jan 27 2026
NASDAQ.COM
Latest Wall Street Ratings Overview
Jan 26 2026
CNBC
Wall Street Analysts Adjust Ratings on Key Stocks
Jan 26 2026
Benzinga
Morgan Stanley Initiates Belite Bio at Overweight with $191 Price Target
Jan 06 2026
CNBC
The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?
Dec 19 2025
NASDAQ.COM
Belite Bio, Inc - Price Target for Depositary Receipt (BLTE) Raised by 62.05% to 188.02
Dec 06 2025
NASDAQ.COM
Belite Bio Prices 2.27M ADS Offering at $154 Each, Raising $350M
Dec 02 2025
Newsfilter
Belite Bio sets price for 2.27 million ADSs at $154.00, aiming to raise $350 million in public offering
Dec 02 2025
SeekingAlpha
HC Wainwright & Co. Reaffirms Buy Rating for Belite Bio, Increases Price Target to $185
Dec 01 2025
Benzinga
Belite Bio Achieves Significant Phase 3 Milestone for Tinlarebant in Treating Stargardt Disease
Dec 01 2025
NASDAQ.COM
Belite Bio Achieves First Successful Phase 3 Trial for Rare Vision Loss Condition
Dec 01 2025
Benzinga
Belite Bio's Tinlarebant Achieves 36% Reduction in Lesion Growth in Phase 3 Stargardt Disease Trial
Dec 01 2025
Newsfilter
Major Stocks Including Alibaba, Oscar Health, Ondas Holdings, Lumentum, and Tesla Rise on Monday
Nov 24 2025
Benzinga
Show More News
